Autopsy report · NCT03822013

Effects of Miglustat Therapy on Infantile Type of Sandhoff and Taysachs Diseases (EMTISTD)

Cause of deathSlow enrollment Automatic label, confidence 0.5, unverified. How labels are made.

“The number of controls was insufficient compared to case.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 6 years 8 months before it stopped.
30 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Tehran University of Medical Sciences
Sponsor type: University, hospital or other
Conditions: GM2 Gangliosidosis; Supportive Care
Interventions: Miglustat
Participants: 30
Sites: 3
Countries: Iran

Trials that died the same way

Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus
“adequate cases were not available” (60% match in meaning)

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.